Oral Nemonoxacin in Treating Elderly Patients With CAP

TaiGen Biotechnology

Status and phase: Completed; Phase 4

Conditions: Community-acquired Pneumonia

Treatments: Drug: Nemonoxacin

Study type: Interventional

Funder types: Industry

Identifiers

NCT05133752

TG-873870-05

Details and patient eligibility

About

This study was to evaluate the safety and efficacy of oral nemonoxacin in treating elderly patients (aged ≥ 65 years) with community-acquired pneumonia (CAP).

Enrollment: 100 patients

Sex: All

Ages: 65+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥65 years
• Clinical diagnosis of CAP
• Evidence of inflammatory exudates or infiltrates on chest X-ray

Exclusion criteria

• Suspect viral pneumonia, aspiration pneumonia, ventilator-associated pneumonia or hospital-acquired pneumonia
• History of hypersensitivity to quinolone or fluoroquinolone

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

Nemonoxacin

Experimental group

Treatment:

Drug: Nemonoxacin